Redefining the Target: Chemotherapeutics as Antiangiogenics
The DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.
Abstract
Angiogenesis, or new blood vessel formation, is now known to play an important role in both growth and metastasis of many cancers. The central importance of angiogenesis and the understanding of how new blood vessels are formed, has led to novel therapies designed to interrupt this process. Though specific antiangiogenic compounds have only recently entered the clinic, they herald a new era, one in which biology is the basis for therapy. The intense interest in angiogenesis has also lead to a re-examination of the activity of many established cytotoxic agents. Claims of antiangiogenic activity abound, unfortunately, with no common criteria and often little evidence of clinical relevance. What are we to think? Have oncologists unknowingly been administering antiangiogenic therapy all these years? If chemotherapeutics are really antiangiogenics in disguise, why have they failed to cure most solid tumors? Might the hard-learned lessons of chemotherapy resistance pertain to the novel antiangiogenics as well? Though we can offer no certain answers to these important questions, we do offer a framework on which to order the rapidly burgeoning literature. We suggest criteria by which a cytotoxic agent might reasonably be considered to have meaningful antiangiogenic activity. Finally, we describe potential mechanisms of resistance to antiangiogenic chemotherapies—some of which may apply to the pure antiangiogenics currently in development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Risau, W. (1997) · Nature · doi:10.1038/386671a0 · Cited by 5,727
Tumor Angiogenesis and Metastasis — Correlation in Invasive Breast Carcinoma
Weidner, N., Semple, J. P., Welch, W. R., & Folkman, J. (1991) · New England Journal of Medicine · doi:10.1056/nejm199101033240101 · Cited by 5,627
What Is the Evidence That Tumors Are Angiogenesis Dependent?
Folkman, J. (1990) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/82.1.4 · Cited by 4,531
Vessel Cooption, Regression, and Growth in Tumors Mediated by Angiopoietins and VEGF
Holash, J., Maisonpierre, P. C., Compton, D., Boland, P., Alexander, C. R., Zagzag, D., Yancopoulos, G. D., & Wiegand, S. J. (1999) · Science · doi:10.1126/science.284.5422.1994 · Cited by 2,195
Gerber, H.-P., McMurtrey, A., Kowalski, J., Yan, M., Keyt, B. A., Dixit, V., & Ferrara, N. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.46.30336 · Cited by 1,981
Genes Expressed in Human Tumor Endothelium
Croix, B. S., Rago, C., Velculescu, V., Traverso, G., Romans, K. E., Montgomery, E., Lal, A., Riggins, G. J., Lengauer, C., Vogelstein, B., et al. (2000) · Science · doi:10.1126/science.289.5482.1197 · Cited by 1,845
The unique physiology of solid tumors: opportunities (and problems) for cancer therapy.
Brown, J. M., & Giaccia, A. J. (1998) · PubMed · Cited by 1,748
Browder, T. D., Butterfield, C., Kräling, B. M., Shi, B., Marshall, B., OʼReilly, M., & Folkman, J. (2000) · PubMed · Cited by 1,720
Basement membrane complexes with biological activity
Kleinman, H. K., McGarvey, M. L., Hassell, J. R., Star, V. L., Cannon, F. B., Laurie, G. W., & Martin, G. R. (1986) · Biochemistry · doi:10.1021/bi00350a005 · Cited by 1,502
Cited by
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E. A., Shenkier, T., Cella, D., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,081
Self-citationRole of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
Hicklin, D. J., & Ellis, L. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.081 · Cited by 3,007
The anti-angiogenic basis of metronomic chemotherapy
Kerbel, R. S., & Kamen, B. A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1369 · Cited by 1,397
Cardiovascular Complications of Cancer Therapy
Yeh, E. T. H., & Bickford, C. L. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.02.050 · Cited by 1,275
Bracci, L., Schiavoni, G., Sistigu, A., & Belardelli, F. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2013.67 · Cited by 928
Cardiovascular Complications of Cancer Therapy: Diagnosis, Pathogenesis, and Management
Yeh, E. T. H., Tong, A. T., Lenihan, D. J., Yusuf, S. W., Swafford, J., Champion, C., Durand, J.-B., Gibbs, H., Zafarmand, A. A., & Ewer, M. S. (2004) · Circulation · doi:10.1161/01.cir.0000133187.74800.b9 · Cited by 843
Metronomic chemotherapy: new rationale for new directions
Pasquier, E., Kavallaris, M., & André, N. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.82 · Cited by 659
Vascular Endothelial Growth Factor as a Target for Anticancer Therapy
Ferrara, N. (2004) · The Oncologist · doi:10.1634/theoncologist.9-suppl_1-2 · Cited by 574
Garcia, A. A., Hirte, H., Fleming, G., Yang, D., Tsao-Wei, D. D., Roman, L., Groshen, S., Swenson, S., Markland, F., Gandara, D., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.1939 · Cited by 547
Antiangiogenic Therapy: A Universal Chemosensitization Strategy for Cancer?
Kerbel, R. S. (2006) · Science · doi:10.1126/science.1125950 · Cited by 466
Broad targeting of angiogenesis for cancer prevention and therapy
Wang, Z., Dabrosin, C., Yin, X., Fuster, M. M., Arreola, A., Rathmell, W. K., Generali, D., Nagaraju, G. P., El-Rayes, B., Ribatti, D., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.01.001 · Cited by 464
Shaked, Y., Henke, E., Roodhart, J. M. L., Mancuso, P., Langenberg, M. H. G., Colleoni, M., Daenen, L. G., Man, S., Xu, P., Emmenegger, U., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.08.001 · Cited by 440
A role for survivin in chemoresistance of endothelial cells mediated by VEGF
Tran, J., Master, Z., Yu, J. L., Rak, J., Dumont, D. J., & Kerbel, R. S. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.072586399 · Cited by 434
Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy
Bocci, G., Francia, G., Man, S., Lawler, J., & Kerbel, R. S. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2135406100 · Cited by 414
Schneider, B. P., & Miller, K. D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.12.017 · Cited by 350
Self-citationMetronomics: towards personalized chemotherapy?
André, N., Carré, M., & Pasquier, E. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.89 · Cited by 320
The molecular pharmacology of symplostatin 1: A new antimitotic dolastatin 10 analog
Mooberry, S. L., Leal, R. M., Tinley, T. L., Luesch, H., Moore, R. E., & Corbett, T. H. (2003) · International Journal of Cancer · doi:10.1002/ijc.10982 · Cited by 87
Naik, E., O'Reilly, L. A., Asselin-Labat, M.-L., Merino, D., Lin, A., Cook, M., Coultas, L., Bouillet, P., Adams, J. M., & Strasser, A. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20100951 · Cited by 31
“The BH3-only protein Bim (O’Connor et al., 1998) is critical for the apoptosis induced by cytokine deprivation in several cell types (Bouillet et al., 1999; Youle and Strasser, 2008), and notably, in early development of the eye, Bim is critical for the programmed cell death of the ECs comprising…”
Background
Metadata
- Authors
- Miller, K. D., Sweeney, C. J., & Sledge, G. W.
- Venue
- Journal of Clinical Oncology
- Published
- 2001-02-15
- Volume
- 19
- Issue
- 4
- Pages
- 1195-1206
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2161714684
- Cited by
- 395
- References
- 93
- FWCI
- 10.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.